Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders... Show more
a product based biopharmaceutical company
Industry PharmaceuticalsGeneric
A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with BIOA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then BIOA could also see price increases.
| Ticker / NAME | Correlation To NBIX | 1D Price Change % | ||
|---|---|---|---|---|
| NBIX | 100% | -0.80% | ||
| BIOA - NBIX | 37% Loosely correlated | -3.95% | ||
| AKBA - NBIX | 32% Poorly correlated | -5.33% | ||
| ALKS - NBIX | 31% Poorly correlated | +0.05% | ||
| KNSA - NBIX | 28% Poorly correlated | +0.82% | ||
| BCRX - NBIX | 26% Poorly correlated | -2.52% | ||
More | ||||
| Ticker / NAME | Correlation To NBIX | 1D Price Change % |
|---|---|---|
| NBIX | 100% | -0.80% |
| Pharmaceuticals: Generic industry (83 stocks) | 7% Poorly correlated | -0.92% |
NBIX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 31 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 58%.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In 50 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Aroon Indicator for NBIX entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Oscillator exited the oversold zone, 17 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 223 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.865) is normal, around the industry mean (43.873). P/E Ratio (20.529) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. NBIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.